Largest Vaccine Study By Research Arm Of The World Health Organization Finds A Variety Of Post-Vaccine Medical Conditions!

COVID-19 News: The advent of COVID-19 vaccines marked a significant milestone in the global effort to combat the pandemic. However, alongside their remarkable efficacy in preventing severe illness and death, concerns have emerged regarding potential adverse events associated with vaccination. Recent findings from the largest vaccine safety study conducted by the Global Vaccine Data Network (GVDN), a research arm of the World Health Organization (WHO), shed light on these concerns. This COVID-19 News report delves into the intricacies of COVID-19 vaccine safety, exploring the nuances of adverse events and their implications.


Largest Vaccine Study By Research Arm Of The World Health Organization
Finds A Variety Of Post-Vaccine Medical Conditions
 
To date, more than 13.5 billion doses of COVID-19 vaccines have been administered globally over the past three years, with claims that over 1 million lives were saved in Europe alone. Still, a small proportion of people immunized were injured by the shots, stoking debate about their benefits versus harms
 
The study looked for 13 medical conditions that the research group considered “adverse events of special interest” among 99 million vaccinated individuals in eight countries, aiming to identify higher-than-expected cases after a COVID-19 vaccine shot.
 
Interestingly, myocarditis, or inflammation of the heart muscle, was consistently identified following a first, second and third dose of mRNA vaccines, the study found.
 
Alarmingly, the highest increase in the observed-to-expected ratio was seen after a second jab with the Moderna shot. dose (6.1 times the expected rate of cases!) A first and fourth dose of the same vaccine was also tied to an increase in pericarditis, or inflammation of the thin sac covering the heart.
 
The study team found a statistically significant increase in cases of Guillain-Barre syndrome within 42 days of an initial Oxford-developed ChAdOx1 shot that wasn’t observed with mRNA vaccines. Based on the background incidence of the condition, 66 cases were expected - but 190 events were observed.

ChAdOx1 was linked to a threefold increase in cerebral venous sinus thrombosis, a type of blood clot in the brain, identified in 69 events, compared with an expected 21.
 
The alarming risk led to the vaccine’s withdrawal or restriction in Denmark and multiple other countries. Myocarditis was also linked to a third dose of ChAdOx1 in some, but not all, populations studied.
 
Another heart condition called pericarditis had a 6.9-fold increased risk in those who took a third dose of AstraZeneca’s viral-vector vaccine, while a first and fourth dose of Moderna’s vaccine had a 1.7-fold and 2.6-fold increased risk, respectively.
 
There was a 2.5-times greater risk of developing the rare autoimmune disorder Guillain-Barre syndrome among those who took AstraZeneca’s vaccine compared to the rate researchers expect ed, and a 3.2-times greater risk of getting blood clots among the same population.
 
There was a 3.8-times greater risk of developing the neurological disorder acute disseminated encephalomyelitis after the Moderna vaccine was administered, and a 2.2-fold increased risk after AstraZeneca’s vaccine, according to the study.
 
Possible safety signals for transverse myelitis - spinal cord inflammation - after viral-vector vaccines was identified in the study.
 
So was acute disseminated encephalomyelitis - inflammation and swelling in the brain and spinal cord – after both viral-vector and mRNA vaccines.
 
Seven cases of acute disseminated encephalomyelitis after vaccination with the Pfizer-BioNTech vaccine were observed, versus an expectation of two.

The adverse events of special interest were selected based on pre-established associations with immunization, what was already known about immune-related conditions and preclinical research.
 
It was noted by many experts that the study didn’t monitor for postural orthostatic tachycardia syndrome, or POTS, that some research has linked with COVID-19 vaccines.

Thailand Medical News would like to add that the study did not include vaccine induced damage to the liver, kidneys and also its possible disruption of cancer protective genes and mechanisms. Thailand Medical News is in fact warning that the vaccines are causing a silent kidney and liver crisis as most are not aware that these organs are affected till the late stages!
 
https://www.thailandmedical.news/news/breaking-news-gene-study-reveals-how-covid-19-mrna-vaccine-leads-to-high-risk-of-iga-nephropathy-eventual-kidney-failure-and-possible-cancers
 
https://www.thailandmedical.news/news/covid-19-mrna-jabs-can-cause-new-onset-of-acute-interstitial-nephritis
 
https://www.thailandmedical.news/news/breaking-international-study-warns-that-pfizer-s-mrna-vaccines-could-be-causing-a-silent-pandemic-of-liver-injury
 
https://www.thailandmedical.news/news/contrary-to-claims-that-covid-19-mrna-jabs-protect-the-vulnerable-cedars-sinai-study-finds-that-they-trigger-pots-in-many-with-underlying-conditions
 
https://www.thailandmedical.news/news/texas-md-anderson-cancer-center-warns-that-covid-19-mrna-vaccines-elevate-pd-l1-levels-disrupting-lung-cancer-treatments-progressing-other-cancers
 
https://www.thailandmedical.news/news/researchers-warn-that-covid-19-jabs-can-cause-central-nervous-system-inflammatory-demyelinating-diseases

Understanding Adverse Events
The study conducted by the GVDN analyzed data from 99 million vaccinated individuals across eight countries, providing invaluable insights into adverse events following COVID-19 vaccination. Among the notable findings were increases in neurological, blood, and heart-related conditions. These included myocarditis, pericarditis, Guillain-Barre syndrome (GBS), cerebral venous sinus thrombosis (CVST), and acute disseminated encephalomyelitis (ADEM).
 
Myocarditis and Pericarditis
Myocarditis, characterized by inflammation of the heart muscle, emerged as a notable adverse event associated with mRNA vaccines, particularly Pfizer-BioNTech and Moderna. The study revealed increased risks of myocarditis following the first, second, and third doses of mRNA vaccines. Notably, the highest increase in myocarditis cases was observed after the second dose of the Moderna vaccine. Similarly, pericarditis, inflammation of the thin sac surrounding the heart, showed elevated risks following mRNA vaccinations. Third doses of AstraZeneca's viral-vector vaccine also exhibited an increased risk of pericarditis.
 
Guillain-Barre Syndrome and Cerebral Venous Sinus Thrombosis
The study identified a higher risk of Guillain-Barre syndrome, a neurological disorder affecting the peripheral nervous system, following vaccination with AstraZeneca's viral-vector vaccine. Additionally, an increased risk of cerebral venous sinus thrombosis, a type of blood clot in the brain, was associated with the same vaccine. These findings underscore the importance of monitoring neurological adverse events post-vaccination.
 
Acute Disseminated Encephalomyelitis
Acute disseminated encephalomyelitis, characterized by inflammation and swelling in the brain and spinal cord, exhibited an elevated risk following both mRNA and viral-vector vaccines. The study found a statistically significant increase in ADEM cases after the first dose of the Moderna vaccine. While the number of cases was relatively small, the implications of such neurological adverse events warrant further investigation.
 
Implications and Considerations
While the study provides crucial insights into COVID-19 vaccine safety, it is essential to contextualize these findings within the broader risk-benefit framework. The risks of adverse events associated with vaccination must be weighed against the potential consequences of COVID-19 infection. Experts emphasize that the benefits of vaccination, including the prevention of severe illness, hospitalization, and death, far outweigh the risks of adverse events.
 
Comparative Analysis
Comparing the risks associated with vaccination to those posed by COVID-19 infection offers valuable perspective. Studies have indicated that the odds of developing adverse events following vaccination are significantly lower than the risks associated with SARS-CoV-2 infection. For instance, the risk of myocarditis post-vaccination is substantially lower than the risk following COVID-19 infection. Similarly, the risk of developing Guillain-Barre syndrome is markedly higher after contracting COVID-19 compared to vaccination.
 
Challenges and Limitations
Despite the comprehensive nature of the study, several challenges and limitations must be acknowledged. Heterogeneity in data collection, quality, and reporting standards across countries may introduce bias and affect the comparability of results. Variations in healthcare infrastructure, surveillance systems, and vaccination strategies further compound these challenges. Moreover, underreporting of adverse events may lead to an underestimation of their significance.
 
Conclusion
The findings from the largest vaccine safety study provide invaluable insights into the complexities of COVID-19 vaccine adverse events. While the study identifies potential safety signals associated with vaccination, it underscores the importance of a nuanced risk-benefit assessment. Vaccination remains a critical tool in mitigating the impact of the pandemic, and efforts to monitor and address vaccine safety concerns must continue. By navigating these complexities with diligence and scientific rigor, we can optimize the safety and efficacy of COVID-19 vaccination programs worldwide.
 
In conclusion, understanding the nuances of COVID-19 vaccine safety is essential for informed decision-making and public health policymaking. As we continue to navigate the complexities of the pandemic, robust surveillance, research, and communication efforts will be instrumental in ensuring the safety and effectiveness of vaccination programs. By prioritizing transparency, collaboration, and evidence-based approaches, we can mitigate risks, build trust, and advance global efforts to overcome the COVID-19 crisis.
 
The study findings were published in the peer reviewed journal: Vaccines.
https://www.sciencedirect.com/science/article/pii/S0264410X24001270
 
For the latest COVID-19 News, keep on logging to Thailand Medical News.